State-backed vaccine manufacturer Biovac expects to produce its first commercial batches of the Pfizer-BioNTech Covid-19 vaccine in October, despite the growing uncertainty about demand for coronavirus shots.

Biovac signed an agreement with Pfizer in July 2021 to fill and finish up to 100-million doses a year for AU members, but with demand for Covid-19 jabs falling worldwide that target looks increasingly uncertain...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.